⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL41738 | 1.00 | — | — | |
| SCHEMBL31365934 | 0.98 | NUDT1 (0.44) | — | |
| Hydrochloric Acid SCHEMBL1813549 | 0.98 | NUDT1 (0.44) | — | |
| Hydrochloric Acid SCHEMBL29424114 | 0.98 | NUDT1 (0.44) | — | |
| SCHEMBL2446689 | 0.98 | NUDT1 (0.44) | — | |
| Hydrochloric Acid SCHEMBL12003889 | 0.98 | NUDT1 (0.44) | — | |
| Hydrochloric Acid SCHEMBL4664431 | 0.98 | NUDT1 (0.44) | — | |
| Iodide SCHEMBL900009 | 0.98 | NUDT1 (0.44) | — | |
| SCHEMBL31249060 | 0.98 | NUDT1 (0.44) | — | |
| SCHEMBL29088005 | 0.98 | NUDT1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 306 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4482583-B1 | ZWITTERIONIC ANTIBACTERIAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2026-04-01 | — | — | EP | claimed |
| US-20260014263-A1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | SAREPTA THERAPEUTICS, INC. (US) | 2026-01-15 | — | — | US | claimed |
| US-12502432-B2 | Bicyclic peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2025-12-23 | — | — | US | claimed |
| EP-4658656-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | Beone Medicines I GmbH (CH) | 2025-12-10 | — | — | EP | claimed |
| US-20250367306-A1 | CHIMERIC PEPTIDES FOR ANTISENSE DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2025-12-04 | — | — | US | claimed |
| EP-4612292-A1 | FORMULATION OF AN ANTISENSE OLIGOMER CONJUGATE | Sarepta Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | claimed |
| EP-4590311-A2 | DMD ANTISENSE OLIGONUCLEOTIDE-MEDIATED EXON SKIPPING EFFICIENCY | Sarepta Therapeutics, Inc. (US) | 2025-07-30 | — | — | EP | claimed |
| US-12370261-B2 | Chimeric peptides for antisense delivery | SAREPTA THERAPEUTICS, INC. (US) | 2025-07-29 | — | — | US | claimed |
| US-20250228954-A1 | Designing Antisense Oligonucleotide Delivery Peptides by Interpretable Machine Learning | SAREPTA THERAPEUTICS INC (US) | 2025-07-17 | — | — | US | claimed |
| EP-4568972-A1 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2025-06-18 | — | — | EP | claimed |
| EP-4306538-A2 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | Sarepta Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | claimed |
| CN-111886233-B | Triazolone derivatives or salts thereof and pharmaceutical compositions containing the same | 柳韩洋行 | 2024-01-02 | — | — | CN | claimed |
| EP-3297649-B1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | SAREPTA THERAPEUTICS INC (US) | 2023-10-11 | — | — | EP | claimed |
| US-20230310625-A1 | Peptide Oligonucleotide Conjugates | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2023-10-05 | — | — | US | claimed |
| US-11672871-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | claimed |
| WO-2023055774-A1 | ANTISENSE OLIGONUCLEOTIDES HAVING ONE OR MORE ABASIC UNITS | SAREPTA THERAPEUTICS, INC. (US) | 2023-04-06 | — | — | WO | claimed |
| WO-2023034515-A2 | DELIVERY OF ANITSENSE OLIGOMERS BY MIRROR IMAGE PEPTIDES | SAREPTA THERAPEUTICS, INC. (US) | 2023-03-09 | — | — | WO | claimed |
| EP-4093441-A1 | DESIGNING ANTISENSE OLIGONUCLEOTIDE DELIVERY PEPTIDES BY INTERPRETABLE MACHINE LEARNING | Sarepta Therapeutics, Inc. (US) | 2022-11-30 | — | — | EP | claimed |
| CN-114651215-A | Photoresist stripping liquid composition for manufacturing display | LTC有限公司 | 2022-06-21 | — | — | CN | claimed |
| US-20220072143-A1 | Peptide Oligonucleotide Conjugates | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2022-03-10 | — | — | US | claimed |